A STUDY FROM THE HARVARD SCHOOL OF PUBLIC HEALTH FOUND THAT HIGHER CHROMIUM STATUS IS ASSOCIATED WITH IMPROVED HEART HEALTH.
According to a scientific presentation at the Experimental Biology conference, functional chromium deficiency may be directly related to a relative lack of chromium in the diet. Numerous studies support this view and demonstrate that chromium supplementation, especially Chromax® chromium picolinate, enhances the metabolic action of insulin and improves lipid metabolism.*
PRE-CLINICAL EVIDENCE HAS SHOWN THAT NITROSIGINE®
DEMONSTRATES SUPERIORITY OVER ARGININE IN BLOOD
FLOW MARKERS AND HAS SIGNIFICANT SILICON ABSORPTION.
Research has shown dramatic protective effects of the novel amino acid compound arginine silicate in pre-clinical studies. The benefits seen in enhancing maximum blood flow can be applied to many health benefits,including cardiovascular health.
A NEW CLINICAL STUDY SUPPORTS NITROSIGINE’S® ABILITY TO ENHANCE THE BENEFITS OF RIGOROUS WORKOUTS BY SIGNIFICANTLY INCREASING NITRIC OXIDE LEVELS.*3
Nitrosigine® is a novel patented complex of inositol-stabilized arginine silicate, accepted by the FDA as a new dietary ingredient. Research has shown significant protective effects of the novel amino acid compound arginine silicate in an animal model of the Metabolic Syndrome with treatment reversing impaired function of the coronary arteries.*3 Nitrosigine® supplementation significantly increased silicon blood levels compared to normal dietary intake.
Nitrosigine® provides the benefits of arginine and silicon, with additional benefits from the unique combination. Arginine has been studied extensively since 1998 as a natural metabolic donor of nitric oxide. There is also accumulated evidence over the past 35 years suggesting an important role for silicon in connective tissue.
Nitrosigine® Science Highlights:
The new clinical study demonstrated significant increases in plasma arginine levels (P<0.01) and serum silicon levels (P<0.01) after a single dose of Nitrosigine®.*3 In addition, a significant increase in nitric oxide levels (measured as salivary nitrites) was seen after 14 days of product consumption (P<0.05).*3
The clinical study that verified daily Nitrosigine® supplementation increased nitric oxide (NO) levels with a significant change in NO levels at 14 days.*3 The increase in NO levels can promote relaxation of smooth muscle in blood vessels, which increases blood flow and improves cardiovascular and muscular health.
Consumer benefits directly linked to the clinical study findings include*3:
• Nitrosigine® significantly boosts nitric oxide (NO) levels, a key factor
in increasing blood flow
• Nitrosigine® is a safe, bioavailable source of arginine and silicon
• Nitrosigine® takes effect in as quickly as 30 minutes
• Nitrosigine® keeps delivering benefits up to 3 hours after a single
• Nitrosigine® significantly increases silicon levels for up to 1.5 hours
• With continued use of Nitrosigine®, nitric oxide levels build over time,
leading to even better blood flow and vessel flexibility.
Research has shown dramatic protective effects of the novel amino acid complex arginine silicate in pre-clinical animal studies.
• Nitrosigine® almost doubles maximum blood flow compared to
Arginine HCl and is 4x greater than Control *1
• Nitrosigine® blood vessel relaxation is almost 5x greater than
Arginine HCl *1
• Nitrosigine® supplementation significantly increased silicon
blood levels compared to normal dietary intake *2
• Higher nitric oxide related maximum blood flow & vessel relaxation
achieved with Nitrosigine® offer many health benefits
For more information, please visit: Nitrosigine.com
*1. Proctor SD, Kelly SE, Russell JC. A novel complex of arginine-silicate improves micro- and macrovascular function and inhibits glomerular sclerosis in insulin-resistant JCR:LA-cp rats. Diabetologia. 2005 Sep;48(9):1925-32.
*2. Proctor SD, Kelly SE, Vine DF, Russell JC. Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat. Metabolism. 2007 Oct;56(10):1318-25.
*3. Presented at The Experimental Biology (EB) 2014 meeting held at the San Diego Convention Center, April 30, 2014 and in the Federation of American Societies for Experimental Biology journal (FASEB).